{"url_path":"/sec/plx/8-k/2026-05-21/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-21","source_url":"https://www.sec.gov/Archives/edgar/data/1006281/0001104659-26-064850-index.html","accession_number":"0001104659-26-064850","cik":"0001006281","ticker":"PLX","issuer_name":"Protalix BioTherapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1006281/0001104659-26-064850-index.html","primary_entity_key":"0001006281","primary_entity_name":"Protalix BioTherapeutics, Inc."},"word_count":343,"has_tables":true,"body_markdown":"Protalix BioTherapeutics, Inc._May 21, 2026\n\n0001006281false00010062812026-05-212026-05-21\n\n​\n\n​\n\n**UNITED STATES**\n\n**SECURITIES AND EXCHANGE COMMISSION**\n\n**Washington, D.C. 20549**\n\n**FORM ****8-K**\n\n**CURRENT REPORT**\n\n**Pursuant to Section 13 or 15(d) of**\n\n**the Securities Exchange Act of 1934**\n\n**Date of Report (Date of Earliest Event Reported):****May 21, 2026**\n\n**Protalix BioTherapeutics, Inc.**\n\n**(Exact name of registrant as specified in its charter)**\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n**Delaware**\n\n**  ​ ​ ​**\n\n**001-33357**\n\n**  ​ ​ ​**\n\n**65-0643773**\n\n**(State or other jurisdiction**\n**of incorporation)**\n\n​\n\n**(Commission File Number)**\n\n​\n\n**(IRS Employer********Identification No.)**\n\n​\n\n​\n\n​\n\n​\n\n​\n\n**2 University Plaza**\n\n​\n\n​\n\n​\n\n​\n\n**Suite 100**\n\n​\n\n​\n\n​\n\n​\n\n**Hackensack****,****NJ**\n\n​\n\n​\n\n​\n\n**07601**\n\n**(Address of principal executive offices)**\n\n​\n\n​\n\n​\n\n**(Zip Code)**\n\n​\n\n **Registrant’s telephone number, including area code****201****-****696-9345**\n\n**(Former name or former address, if changed since last report.)**\n\nCheck the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):\n\n☐    Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)\n\n☐    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)\n\n☐    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))\n\n☐    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))\n\n​\n\n**Securities registered pursuant to Section 12(b) of the Act:**\n\n​\n\nTitle of each class\n\nTrading Symbol(s)\n\nName of each exchange on which registered\n\nCommon stock, $0.001 par value\n\nPLX\n\nNYSE American\n\n​\n\nIndicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).\n\nEmerging growth company ☐\n\nIf an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ◻\n\n​\n\n​\n\n​"}